Mesirow Financial Investment Management Inc. boosted its position in shares of CME Group Inc. (NASDAQ:CME – Free Report) by 5.6% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,633 shares of the financial services provider’s stock after buying an additional 672 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in CME Group were worth $2,491,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the company. Bluefin Capital Management LLC acquired a new position in shares of CME Group in the 4th quarter valued at $2,891,000. Alaska Permanent Fund Corp lifted its stake in shares of CME Group by 81.4% in the 1st quarter. Alaska Permanent Fund Corp now owns 44,534 shares of the financial services provider’s stock valued at $9,588,000 after purchasing an additional 19,985 shares during the period. Western Pacific Wealth Management LP lifted its stake in shares of CME Group by 20.2% in the 4th quarter. Western Pacific Wealth Management LP now owns 523 shares of the financial services provider’s stock valued at $110,000 after purchasing an additional 88 shares during the period. Bank of Nova Scotia lifted its stake in shares of CME Group by 229.4% in the 4th quarter. Bank of Nova Scotia now owns 292,597 shares of the financial services provider’s stock valued at $61,618,000 after purchasing an additional 203,769 shares during the period. Finally, Oak Harvest Investment Services raised its stake in CME Group by 66.5% during the 1st quarter. Oak Harvest Investment Services now owns 45,093 shares of the financial services provider’s stock worth $9,708,000 after buying an additional 18,017 shares during the period. Institutional investors and hedge funds own 87.75% of the company’s stock.
Insider Buying and Selling
In related news, Director Bryan T. Durkin sold 7,593 shares of CME Group stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $214.59, for a total transaction of $1,629,381.87. Following the completion of the transaction, the director now owns 55,607 shares in the company, valued at $11,932,706.13. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.30% of the stock is currently owned by corporate insiders.
CME Group Price Performance
CME Group (NASDAQ:CME – Get Free Report) last announced its quarterly earnings data on Wednesday, July 24th. The financial services provider reported $2.56 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.03. The company had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.53 billion. CME Group had a return on equity of 12.82% and a net margin of 56.98%. CME Group’s revenue for the quarter was up 12.7% compared to the same quarter last year. During the same quarter last year, the company earned $2.30 EPS. As a group, sell-side analysts predict that CME Group Inc. will post 9.94 earnings per share for the current fiscal year.
CME Group Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Monday, September 9th will be issued a dividend of $1.15 per share. This represents a $4.60 dividend on an annualized basis and a yield of 2.10%. The ex-dividend date is Monday, September 9th. CME Group’s payout ratio is currently 52.33%.
Wall Street Analyst Weigh In
Several brokerages recently commented on CME. Piper Sandler reaffirmed an “overweight” rating and set a $225.00 price objective on shares of CME Group in a research note on Tuesday, August 20th. Barclays raised their price objective on CME Group from $208.00 to $209.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 25th. Bank of America downgraded CME Group from a “neutral” rating to an “underperform” rating and dropped their price objective for the stock from $212.00 to $177.00 in a research note on Tuesday, September 3rd. Keefe, Bruyette & Woods raised their price objective on CME Group from $212.00 to $213.00 and gave the stock a “market perform” rating in a research note on Thursday, July 25th. Finally, JPMorgan Chase & Co. increased their target price on CME Group from $187.00 to $191.00 and gave the stock an “underweight” rating in a report on Thursday, July 25th. Four investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $209.73.
Check Out Our Latest Stock Analysis on CME
CME Group Company Profile
CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.
Read More
- Five stocks we like better than CME Group
- How to invest in marijuana stocks in 7 stepsĀ
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- How Investors Can Find the Best Cheap Dividend Stocks
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What Are Dividend Achievers? An Introduction
- 5 Oversold Stocks to Buy Right Now
Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME – Free Report).
Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.